Lentiviral Vector Market Report 2026

The lentiviral vector market size has grown rapidly in recent years. It will grow from $16.48 billion in 2025 to $18.95 billion in 2026 at a compound annual growth rate (CAGR) of 15%. The growth in the historic period can be attributed to development of stable lentiviral production methods, increasing prevalence of genetic disorders, growth in academic and clinical research, rising investments in gene therapy R&D, availability of transduction and packaging kits.

The lentiviral vector market size is expected to see rapid growth in the next few years. It will grow to $30.66 billion in 2030 at a compound annual growth rate (CAGR) of 12.8%. The growth in the forecast period can be attributed to expansion of gene therapy pipelines, adoption of automated vector production systems, collaborations between biotech and pharma companies, emergence of novel lentiviral vector applications, increased demand from emerging markets. Major trends in the forecast period include gene therapy adoption growth, viral vector engineering advancements, regulatory compliance & approval acceleration, increased research funding for genetic disorders, expansion of contract manufacturing capabilities.

The rising prevalence of chronic diseases is expected to drive the growth of the lentiviral vectors market in the coming years. Chronic diseases are long-term medical conditions that typically progress slowly and often persist for years or even a lifetime. Factors such as aging populations, unhealthy lifestyles, urbanization, and environmental influences are contributing to the increasing prevalence of these conditions. Lentiviral vectors provide versatile and efficient tools for developing vaccines and therapeutic strategies for chronic diseases, addressing unmet medical needs and improving patient outcomes. For instance, in September 2024, the British Heart Foundation, a UK-based cardiovascular research charity, reported that approximately 7.6 million people in the UK are affected by heart and circulatory diseases, including around 4 million males and 3.6 million females. These conditions account for about 27% of all deaths in the UK, translating to over 170,000 deaths annually, or roughly 480 deaths per day, equating to one death every three minutes. Therefore, the increasing prevalence of chronic diseases is contributing to the growth of the lentiviral vectors market.

Major companies operating in the lentiviral vectors market are focusing on developing LV vector production platforms, such as LentiSure, to improve the efficiency and reliability of producing lentiviral vectors for cell-based immuno-oncology therapies. LentiSure is an LV vector production platform designed to enhance both efficiency and robustness in generating lentiviral vectors for therapeutic applications. For instance, in May 2023, Yposkesi SK pharmteco, a France-based viral vector manufacturer, launched LentiSure, an advanced platform aimed at improving the production of lentiviral (LV) vectors. This platform addresses the growing demand for robust and economically scalable viral-vector manufacturing technologies in cell and gene therapies. It provides consistent product quality, achieving average titers of 10e7 IG/mL at cell culture harvest in bioreactor volume, ensuring higher productivity and success for cell therapy developers.

In September 2024, Kyverna Therapeutics Inc., a US-based clinical-stage biopharmaceutical company, entered into a license and supply agreement for the LentiVector platform with Oxford Biomedica. This collaboration allows Kyverna to utilize Oxford Biomedica’s proprietary lentiviral vector technology for the development of gene therapies, particularly for autoimmune diseases. The agreement supports growth and innovation in the lentiviral vector market by providing a scalable and reliable vector supply to meet increasing demand. Oxford Biomedica, a UK-based biotechnology company, specializes in providing lentiviral vector platforms.

Major companies operating in the lentiviral vector market are Thermo Fisher Scientific Inc., Lonza Group AG, Cytiva, Takara Bio Inc., Promega Corporation, Bio-Rad Laboratories Inc., Merck KGaA, Agilent Technologies Inc., Oxford Biomedica, Sirion-Biotech GmbH, Yposkesi, Applied Biological Materials Inc., OriGene Technologies Inc., Sino Biological Inc., Charles River Laboratories, Vigene Biosciences, VectorBuilder, Cell Biolabs Inc., Addgene, GeneCopoeia Inc.

North America was the largest region in the lentiviral vector market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lentiviral vector market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the lentiviral vector market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the lentiviral vector market by increasing the cost of imported raw materials, reagents, and consumables critical for vector production. These tariffs have primarily affected regions in North America and Europe, where significant imports of kits and reagents originate from Asia-Pacific manufacturing hubs. The most impacted segments include lentiviral vector production kits and packaging reagents, which face cost escalation and potential supply delays. However, tariffs have also incentivized local manufacturing initiatives and supply chain diversification, leading to more resilient production networks and potential long-term cost optimization.

The lentiviral vector market research report is one of a series of new reports that provides lentiviral vector market statistics, including lentiviral vector industry global market size, regional shares, competitors with a lentiviral vector market share, detailed lentiviral vector market segments, market trends and opportunities, and any further data you may need to thrive in the lentiviral vector industry. This lentiviral vector market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

A lentiviral vector is a type of viral vector derived from lentiviruses, a subgroup of retroviruses known for their ability to integrate genetic material into the DNA of the host cell genome. These vectors are widely used in molecular biology and gene therapy to deliver genetic material into target cells for purposes such as gene expression, gene silencing, or genetic modification.

The main types of products in the lentiviral vector category include kits, reagents, and consumables. Lentiviral vector kits provide a complete set of tools and components necessary for the production and manipulation of lentiviral vectors. They are used for various applications, including cancer, genetic disorders, infectious diseases, veterinary diseases, and others, and serve a range of users such as biotechnology companies, pharmaceutical companies, contract research organizations (CROs), and academic and research institutions.

The lentiviral vector market consists of sales of 3rd generation lentiviral vectors, Lenti-ORF clones, and lentiviral particles. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.